#reimaginemedicine — Public Fediverse posts

https://www.europesays.com/ch/142184/ Novartis Rhapsido® (remibrutinib) receives FDA approval as #ChronicIllness #Innovation #MediaRelease #Novartis #NovartisPharmaAG #ReimagineMedicine #SwissStockExchange:NOVNSW

https://www.europesays.com/ch/132621/ Novartis US Invests in Data and AI Capabilities for 6,000 Employees #CellTherapy #digital #EmergingTechnology #FutureOfHealthcare #GeneTherapy #GlobalHealthcareCompanies #Innovation #InnovativeHealthcare #InnovativeMedicines #Novartis #NovartisOncologyPipeline #NovartisPharmaceuticals #OncologyDrugDevelopment #RareDiseasePatients #RareDiseaseTreatment #ReimagineMedicine #sandoz #SandozPharmaceuticals #WorkingAtNovartis

https://www.europesays.com/ch/127937/ Novartis provides update on delpacibart etedesiran #AdHoc #MediaRelease #Neuroscience #Novartis #NovartisPharmaAG #ReimagineMedicine #ScientificResearch #SwissStockExchange:NOVNSW

https://www.europesays.com/ch/126338/ Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) #AdHoc #ChronicIllness #Innovation #Novartis #ReimagineMedicine

https://www.europesays.com/ch/126202/ Novartis announces Lp(a)HORIZON Phase III topline results #AdHoc #ChronicIllness #Innovation #MediaRelease #Novartis #NovartisPharmaAG #ReimagineMedicine #SwissStockExchange:NOVNSW

https://www.europesays.com/ch/125262/ FDA approves Pluvicto® for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease #Innovation #Novartis #ReimagineMedicine

https://www.europesays.com/ch/123500/ Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials #AdHoc #MedicalInnovations #Neuroscience #Novartis #ReimagineMedicine

https://www.europesays.com/ch/120646/ Novartis agrees to acquire Myricx Bio, advancing #MediaRelease #Novartis #NovartisPharmaAG #Oncology #ReimagineMedicine #SwissStockExchange:NOVNSW

https://www.europesays.com/ch/119426/ Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA) #CellAndGeneTherapy #Neuroscience #Novartis #RareDiseases #ReimagineMedicine

https://www.europesays.com/ch/117608/ Novartis data at ESC Congress 2026 reinforce cardiovascular #ClinicalTrials #DrugDevelopment #MediaRelease #Novartis #NovartisPharmaAG #ReimagineMedicine #ScientificResearch #SwissStockExchange:NOVNSW

https://www.europesays.com/ch/112699/ Novartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next #CellTherapy #FutureOfHealthcare #GeneTherapy #GlobalHealthcareCompanies #Innovation #InnovativeHealthcare #InnovativeMedicines #Novartis #NovartisOncologyPipeline #NovartisPharmaceuticals #OncologyDrugDevelopment #RareDiseasePatients #RareDiseaseTreatment #ReimagineMedicine #sandoz #SandozPharmaceuticals #ScientificDiscoveries #WorkingAtNovartis

https://www.europesays.com/ch/112338/ Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed #AdHoc #MedicalInnovations #Novartis #ReimagineMedicine

https://www.europesays.com/ch/108897/ Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed #AdHoc #MedicalInnovations #Novartis #ReimagineMedicine

https://www.europesays.com/ch/108730/ Novartis delivered sales growth in Q2 and further advanced #AdHoc #MediaRelease #MedicalInnovations #Novartis #NovartisPharmaAG #ReimagineMedicine #SwissStockExchange:NOVNSW

https://www.europesays.com/ch/107808/ Novartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next #CellTherapy #FutureOfHealthcare #GeneTherapy #GlobalHealthcareCompanies #Innovation #InnovativeHealthcare #InnovativeMedicines #Novartis #NovartisOncologyPipeline #NovartisPharmaceuticals #OncologyDrugDevelopment #RareDiseasePatients #RareDiseaseTreatment #ReimagineMedicine #sandoz #SandozPharmaceuticals #ScientificDiscoveries #WorkingAtNovartis

https://www.europesays.com/ch/107444/ Novartis delivered sales growth in Q2 and further advanced #AdHoc #MediaRelease #MedicalInnovations #Novartis #NovartisPharmaAG #ReimagineMedicine #SwissStockExchange:NOVNSW

https://www.europesays.com/ch/104742/ Novartis Fabhalta® (iptacopan) receives FDA traditional #DrugDevelopment #MediaRelease #Novartis #NovartisPharmaAG #ReimagineMedicine #ScientificDiscoveries #ScientificResearch #SwissStockExchange:NOVNSW

https://www.europesays.com/ch/103803/ The Future of Autoimmune Disease: A Q&A You Need to Read #CellAndGeneTherapy #CellTherapy #FutureOfHealthcare #GeneTherapy #GlobalHealthcareCompanies #Immunology #Innovation #InnovativeHealthcare #InnovativeMedicines #MedicalInnovations #Novartis #NovartisOncologyPipeline #NovartisPharmaceuticals #OncologyDrugDevelopment #PatientEducation #PatientVoices #RareDiseasePatients #RareDiseaseTreatment #ReimagineMedicine #sandoz #SandozPharmaceuticals #ScientificResearch

https://www.europesays.com/ch/99303/ Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients #Novartis #Oncology #ReimagineMedicine

https://www.europesays.com/ch/98973/ A Conversation Women Wish They’d Had: Understanding the Risk of Breast Cancer Coming Back #cancer #CellTherapy #DataScience #FutureOfHealthcare #GeneTherapy #GlobalHealthcareCompanies #InnovativeHealthcare #InnovativeMedicines #LivingWithDisease #Novartis #NovartisOncologyPipeline #NovartisPharmaceuticals #OncologyDrugDevelopment #PatientVoices #RareDiseasePatients #RareDiseaseTreatment #ReimagineMedicine #sandoz #SandozPharmaceuticals

Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)

First gene replacement therapy in the EU for broad population with SMA, including children two years and older,…
#Europe #EU #EuropeanCommission #CellandGeneTherapy #neuroscience #Novartis #rarediseases #ReimagineMedicine
https://www.europesays.com/europe/84540/

https://www.europesays.com/ch/88640/ Novartis agrees to acquire a pan-mutant-selective PI3Kα #cancer #MediaRelease #MedicalInnovations #Novartis #NovartisPharmaAG #Oncology #ReimagineMedicine #SwissStockExchange:NOVNSW

https://www.europesays.com/ch/88181/ Novartis Cosentyx® PMR data in New England Journal of #ChronicIllness #Innovation #MediaRelease #Novartis #NovartisPharmaAG #ReimagineMedicine #SwissStockExchange:NOVNSW

https://www.europesays.com/ch/82531/ Novartis RemIND data at EAACI show Rhapsido® potential as #ChronicIllness #Innovation #MediaRelease #Novartis #NovartisPharmaAG #ReimagineMedicine #SwissStockExchange:NOVNSW

https://www.europesays.com/ch/82249/ Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years #ClinicalTrials #Innovation #Novartis #RareDiseases #ReimagineMedicine

https://www.europesays.com/ch/79430/ Novartis to highlight Rhapsido® data across multiple #ChronicIllness #Innovation #MediaRelease #Novartis #NovartisPharmaAG #ReimagineMedicine #SwissStockExchange:NOVNSW

https://www.europesays.com/ch/77782/ Novartis IgAN data in The Lancet show clinically meaningful #ClinicalTrials #Innovation #MediaRelease #Novartis #NovartisPharmaAG #RareDiseases #ReimagineMedicine #SwissStockExchange:NOVNSW

https://www.europesays.com/ch/77290/ Novartis Cosentyx® PMR data in New England Journal of #ChronicIllness #Innovation #MediaRelease #Novartis #NovartisPharmaAG #ReimagineMedicine #SwissStockExchange:NOVNSW

https://www.europesays.com/ch/76809/ Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases #ChronicIllness #ClinicalTrials #Innovation #Novartis #ReimagineMedicine

https://www.europesays.com/ch/75851/ Novartis data at EULAR 2026 demonstrates momentum for broad #ChronicIllness #ClinicalTrials #Innovation #MediaRelease #Novartis #NovartisPharmaAG #ReimagineMedicine #SwissStockExchange:NOVNSW

Novartis Rhapsido® receives European Commission approval

Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 & 2 studies of highly…
#Europe #EU #EuropeanCommission #ChronicIllness #innovation #mediarelease #NovartisPharmaAG #ReimagineMedicine #SwissStockExchange:NOVN.SW #TargetedTherapy
https://www.europesays.com/europe/23661/

https://www.europesays.com/ie/359641/ Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients #ClinicalResearch #Éire #Health #HealthCare #Healthcare #IE #innovation #Ireland #novartis #ReimagineMedicine #ScientificResearch

https://www.europesays.com/ie/356119/ Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients #ClinicalResearch #Éire #Health #HealthCare #Healthcare #IE #innovation #Ireland #novartis #ReimagineMedicine #ScientificResearch

Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)

Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1Remibrutinib,…
#NewsBeep #News #Medication #AU #Australia #chronicillness #clinicaltrials #Health #Innovation #Novartis #ReimagineMedicine
https://www.newsbeep.com/au/495614/

Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)

Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1Remibrutinib,…
#NewsBeep #News #Medication #CA #Canada #chronicillness #clinicaltrials #Health #Innovation #novartis #ReimagineMedicine
https://www.newsbeep.com/ca/490865/

https://www.europesays.com/ie/349704/ Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU) #ChronicIllness #ClinicalTrials #Éire #Health #IE #innovation #Ireland #Medication #novartis #ReimagineMedicine

https://www.europesays.com/uk/780306/ Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU) #ChronicIllness #ClinicalTrials #Health #Innovation #Medication #Novartis #ReimagineMedicine #UK #UnitedKingdom

https://www.europesays.com/uk/761771/ Novartis Vanrafia® Phase III data support slowing of kidney function decline in patients with IgA nephropathy #Innovation #Novartis #ReimagineMedicine #UnitedStates #us #USA

Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery

New facility will enable end‑to‑end discovery across key disease areas and technology platforms, joining existing global research sites…
#NewsBeep #News #Healthcare #clinicalresearch #Health #healthcare #Innovation #novartis #ReimagineMedicine #ScientificResearch #UK #UnitedKingdom
https://www.newsbeep.com/uk/413232/

https://www.europesays.com/uk/747877/ Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery #ClinicalResearch #Health #Healthcare #Innovation #Novartis #ReimagineMedicine #ScientificResearch #UK #UnitedKingdom

https://www.europesays.com/ie/324532/ Novartis breaks ground on new global Biomedical Research center in San Diego to accelerate drug discovery #ClinicalResearch #Éire #Health #HealthCare #Healthcare #IE #innovation #Ireland #novartis #ReimagineMedicine #ScientificResearch

Novartis and US government reach agreement on lowering drug prices in the US

Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricingAdditional Novartis medicines will be…
#NewsBeep #News #Healthcare #AU #Australia #chronicillness #Health #Innovation #Novartis #ReimagineMedicine
https://www.newsbeep.com/au/359094/

Novartis and US government reach agreement on lowering drug prices in the US

Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricingAdditional Novartis medicines will be…
#NewsBeep #News #Healthcare #CA #Canada #chronicillness #Health #Innovation #novartis #ReimagineMedicine
https://www.newsbeep.com/ca/356296/

https://www.europesays.com/ie/241682/ Novartis and US government reach agreement on lowering drug prices in the US #ChronicIllness #Éire #Health #HealthCare #Healthcare #IE #innovation #Ireland #novartis #ReimagineMedicine

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III…
#NewsBeep #News #Business #Adhoc #ChronicIllness #ClinicalTrials #GB #novartis #ReimagineMedicine #UK #UnitedKingdom
https://www.newsbeep.com/uk/62778/

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III…
#NewsBeep #News #Business #Adhoc #ChronicIllness #ClinicalTrials #GB #novartis #ReimagineMedicine #UK #UnitedKingdom
https://www.newsbeep.com/uk/62778/

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III…
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Business #AdHoc #chronicillness #Clinicaltrials #novartis #ReimagineMedicine
https://www.newsbeep.com/us/76887/

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III…
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Business #AdHoc #chronicillness #Clinicaltrials #novartis #ReimagineMedicine
https://www.newsbeep.com/us/76887/

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III…
#NewsBeep #News #Headlines #AdHoc #ChronicIllness #ClinicalTrials #Latvia #LV #novartis #ReimagineMedicine
https://www.newsbeep.com/53037/